JAZZ Jazz Pharmaceuticals plc
Research report · from SEC EDGAR · close 2026-07-13
$236.97 -2.8%
$14.87B mkt cap
executive summary
Jazz Pharmaceuticals plc (JAZZ) is a $14.87B company. Revenue is $4.27B (+4.9% y/y) at a -8% net margin. It is not yet profitable. Our health score is B (79/100). No major red flags on file. Held by 1 tracked funds. It funds itself; low dilution risk.
Revenue (FY)
$4.27B
+4.9% y/y
✓ No major red flags from our filing-based checks.
who's buying
Insider buys / sells
0 / 11
Cash & ST investments
$1.84B
Operating cash flow
$1.36B
Assembled from SEC EDGAR (XBRL, Form 4, 13F, filings), STOCK Act disclosures, and end-of-day prices — every figure is real and sourced; nothing is fabricated or predicted. Filings lag 40–90 days. Educational, not investment advice. Generated 2026-07-13 by stocktools.ai.